jun 4, 2018: 2:30 p.m. - 3:45 p.m.
Room 206AB, Level 2
The translational pipeline of medical innovation that flows from academic research centers is at the heart of modern society’s ability to turn the explosion of biological discovery into transformative new medicines. A variety of different models have emerged to overcome the inherent challenges in identifying and advancing biological discoveries to a point where they become investable and can attract private sector partners capable of completing their development, regulatory approval and commercialization. However, most of these models involve academic medical centers, pharma companies and venture investors in the established biotech hubs.
This panel will explore how four distinctive programs that lie outside the flourishing ecosystems of the major biotech centers have been navigating the translational landscape and turning inventions into investable innovations.